Charles Schwab Investment Management Inc. Has $26.34 Million Holdings in Ingevity Co. (NYSE:NGVT)

Charles Schwab Investment Management Inc. lifted its position in Ingevity Co. (NYSE:NGVT - Free Report) by 6.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 646,267 shares of the company's stock after acquiring an additional 38,639 shares during the period. Charles Schwab Investment Management Inc. owned approximately 1.78% of Ingevity worth $26,335,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. First Horizon Advisors Inc. raised its holdings in Ingevity by 45.9% in the third quarter. First Horizon Advisors Inc. now owns 862 shares of the company's stock worth $34,000 after purchasing an additional 271 shares during the period. KBC Group NV increased its position in shares of Ingevity by 50.8% in the 3rd quarter. KBC Group NV now owns 1,574 shares of the company's stock valued at $61,000 after buying an additional 530 shares in the last quarter. Empowered Funds LLC acquired a new stake in Ingevity during the 4th quarter worth $187,000. Hennion & Walsh Asset Management Inc. bought a new position in Ingevity during the fourth quarter worth about $239,000. Finally, XTX Topco Ltd acquired a new position in Ingevity in the third quarter valued at about $260,000. Institutional investors own 91.59% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have commented on NGVT shares. StockNews.com upgraded shares of Ingevity from a "hold" rating to a "buy" rating in a report on Thursday, February 20th. BMO Capital Markets upgraded shares of Ingevity from a "market perform" rating to an "outperform" rating and raised their price objective for the stock from $62.00 to $65.00 in a report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $55.17.

Remove Ads

Ingevity Stock Down 2.0 %

Shares of NGVT traded down $0.88 during mid-day trading on Friday, hitting $42.26. 216,391 shares of the company's stock were exchanged, compared to its average volume of 256,505. The company has a debt-to-equity ratio of 6.86, a current ratio of 1.87 and a quick ratio of 1.04. Ingevity Co. has a 52 week low of $30.90 and a 52 week high of $56.30. The company has a market cap of $1.54 billion, a PE ratio of -3.57 and a beta of 1.53. The company has a 50-day simple moving average of $45.20 and a 200 day simple moving average of $42.26.

Ingevity (NYSE:NGVT - Get Free Report) last released its earnings results on Tuesday, February 18th. The company reported $0.95 earnings per share for the quarter, beating analysts' consensus estimates of $0.29 by $0.66. Ingevity had a negative net margin of 30.60% and a positive return on equity of 41.44%. The business had revenue of $298.80 million during the quarter, compared to the consensus estimate of $297.40 million. On average, research analysts forecast that Ingevity Co. will post 4.45 earnings per share for the current fiscal year.

About Ingevity

Ingevity Corporation manufactures and sells activated carbon products, derivative specialty chemicals, and engineered polymers in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. It operates through three segments: Performance Materials, Performance Chemicals, and Advanced Polymer Technologies.